Type 2 Diabetes: Pipeline Review, H1 2018 - ResearchAndMarkets.com

June 12, 2018

DUBLIN--(BUSINESS WIRE)--Jun 12, 2018--The “Type 2 Diabetes - Pipeline Review, H1 2018” report has been added to ResearchAndMarkets.com’s offering.

This latest pipeline guide provides comprehensive information on the therapeutics under development for Type 2 Diabetes (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 2 Diabetes (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type2 diabetes and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 10, 2, 29, 63, 72, 6, 220, 65 and 12 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 1, 62 and 18 molecules, respectively.

Key Topics Covered

Introduction Type 2 diabetes - Overview Type 2 diabetes - Therapeutics Development Type 2 diabetes - Therapeutics Assessment Type 2 diabetes - Companies Involved in Therapeutics Development Type 2 diabetes - Drug Profiles Type 2 diabetes - Dormant Projects Type 2 diabetes - Discontinued Products Type 2 diabetes - Product Development Milestones Appendix

Companies Mentioned

Amgen Inc Aphios Corp Arecor Ltd Arena Pharmaceuticals Inc AstraZeneca Plc AusBio Ltd Avadel Pharmaceuticals Plc Bayer AG Boehringer Ingelheim GmbH Boston Therapeutics Inc Bristol-Myers Squibb Co C4X Discovery Holdings PLC Cadila Healthcare Ltd Daewoong Pharmaceutical Co Ltd Eli Lilly and Co F. Hoffmann-La Roche Ltd Gilead Sciences Inc GlaxoSmithKline Plc Hyundai Pharmaceutical Co Ltd JHL Biotech Inc Johnson & Johnson Kissei Pharmaceutical Co Ltd LG Chem Ltd MedImmune LLC Merck & Co Inc Mitsubishi Chemical Holdings Corp Novartis AG Novo Nordisk AS Pfizer Inc Renova Therapeutics Inc Sanofi SK Chemicals Co Ltd Takeda Pharmaceutical Co Ltd Teijin Pharma Ltd Toray Industries Inc

For more information about this report visit https://www.researchandmarkets.com/research/qr59lz/type_2_diabetes?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180612005758/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Endocrine and Metabolic Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/12/2018 07:10 AM/DISC: 06/12/2018 07:11 AM


Update hourly